Director at Collegium (NASDAQ: COLL) receives 8,741 RSUs in equity award

Rhea-AI Filing Summary

Balice-Gordon Rita J. reported acquisition or exercise transactions in this Form 4 filing.

COLLEGIUM PHARMACEUTICAL director Rita J. Balice-Gordon received an equity grant in the form of restricted stock units (RSUs). The award covers 8,741 RSUs, each representing one share of common stock, and increases her direct holdings to 61,370 shares after the transaction.

The RSUs vest on the earlier of May 14, 2027, or the company’s 2027 Annual Meeting of Shareholders, as long as she continues serving as a director. Settlement occurs in shares on that vesting date or, if she elects, at the end of her board service, upon death or disability, or upon a change in control of the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Balice-Gordon Rita J.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	8,741	$0.00	--

Holdings After Transaction: Common Stock — 61,370 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 8,741 RSUs Shares per RSU: 1 share per RSU Holdings after grant: 61,370 shares +1 more

4 metrics

RSU grant size 8,741 RSUs Equity award to director on May 14, 2026

Shares per RSU 1 share per RSU Each RSU represents one share of common stock

Holdings after grant 61,370 shares Director’s direct common stock holdings following the transaction

Vesting date trigger May 14, 2027 Vests on this date or at the 2027 Annual Meeting, whichever is earlier

Key Terms

restricted stock units, Annual Meeting of Shareholders, change in control, Board of Directors

4 terms

restricted stock units financial

"Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Annual Meeting of Shareholders regulatory

"The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

change in control financial

"on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Board of Directors regulatory

"the end of the director's service on the Board of Directors, the director's death or disability"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Balice-Gordon Rita J.

(Last) (First) (Middle)

C/O COLLEGIUM PHARMACEUTICAL, INC.

100 TECHNOLOGY CENTER DRIVE

(Street)

STOUGHTON MASSACHUSETTS 02072

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
COLLEGIUM PHARMACEUTICAL, INC [ COLL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		A(1)		8,741	A	$0	61,370	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Colleen Tupper as Attorney-In-Fact For Rita J. Balice-Gordon	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did COLLEGIUM PHARMACEUTICAL (COLL) disclose in this Form 4?

COLLEGIUM PHARMACEUTICAL reported that director Rita J. Balice-Gordon received 8,741 restricted stock units. Each RSU represents one share of common stock and increases her direct holdings to 61,370 shares following the grant, reflecting routine equity-based director compensation.

How many COLLEGIUM PHARMACEUTICAL (COLL) shares were granted to the director?

The director was granted 8,741 restricted stock units tied to COLLEGIUM PHARMACEUTICAL common stock. Each RSU equals one share upon settlement, representing an equity award rather than a cash transaction and contributing to the director’s long-term ownership stake in the company.

When do the COLLEGIUM PHARMACEUTICAL (COLL) RSUs vest for the director?

The RSUs vest on the earlier of May 14, 2027, or COLLEGIUM PHARMACEUTICAL’s 2027 Annual Meeting of Shareholders. Vesting is conditioned on the director’s continued service with the company through that date, aligning the grant with ongoing board tenure.

How will the COLLEGIUM PHARMACEUTICAL (COLL) RSUs be settled?

The RSUs will be settled in shares of COLLEGIUM PHARMACEUTICAL common stock. Settlement occurs at vesting or, if the director elects, at the earlier of end of board service, death or disability, or a change in control, providing flexibility in timing.

What is the director’s COLLEGIUM PHARMACEUTICAL (COLL) ownership after this RSU grant?

After the RSU grant, the director’s reported direct holdings are 61,370 shares of COLLEGIUM PHARMACEUTICAL common stock. This figure reflects her position following the equity award and helps indicate the scale of her ownership stake in the company.

Did the COLLEGIUM PHARMACEUTICAL (COLL) director buy or sell shares on the market?

The filing shows an acquisition coded as a grant or award, not an open-market trade. The director received 8,741 restricted stock units at no stated purchase price, indicating compensation-related equity rather than a discretionary market purchase or sale.